Covington Investment Advisors Inc. Makes New $5.29 Million Investment in Stryker Corporation $SYK

Key Points

• Covington Investment Advisors initiated a $5.29 million position in Stryker during the second quarter by purchasing 16,792 shares. Institutional investors collectively own approximately 77.1% of the company.
• Stryker reported better-than-expected quarterly results, with EPS of $3.69 and revenue of $6.59 billion, up 9.4% year over year. The company maintained its fiscal 2026 EPS guidance of $14.95–$15.10 and declared a quarterly dividend of $0.88.
• Analysts remain broadly positive, with a consensus “Moderate Buy” rating and an average price target of $386.28, but several firms have reduced targets amid execution risks and recent insider selling totaling roughly $216.2 million over 90 days.

Covington Investment Advisors Inc. bought a new stake in shares of Stryker Corporation (NYSE:SYK - Free Report) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 16,792 shares of the medical technology company's stock, valued at approximately $5,287,000.

A number of other hedge funds have also recently made changes to their positions in the stock. Brighton Jones LLC increased its position in Stryker by 15.4% during the 4th quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company's stock valued at $1,643,000 after buying an additional 609 shares in the last quarter. Schnieders Capital Management LLC. bought a new stake in Stryker in the second quarter worth $205,000. Marshall Wace LLP grew its stake in shares of Stryker by 107.9% in the second quarter. Marshall Wace LLP now owns 5,700 shares of the medical technology company's stock worth $2,255,000 after acquiring an additional 77,831 shares during the last quarter. Nebula Research & Development LLC purchased a new stake in shares of Stryker in the second quarter worth $219,000. Finally, HUB Investment Partners LLC bought a new position in shares of Stryker during the second quarter valued at $253,000. 77.09% of the stock is owned by institutional investors.

Key Headlines Impacting Stryker

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Stryker’s long-term outlook remains supported by steady demand for its medical technologies, continued Mako robotics growth and improving margins. The company’s latest quarter exceeded expectations, with earnings of $3.69 per share on $6.59 billion in revenue, while revenue increased 9.4% year over year. Here's Why You Should Hold Stryker Stock in Your Portfolio for Now
• Positive Sentiment: Wall Street remains broadly constructive: consensus calls for a “Moderate Buy” rating, with 18 analysts recommending Buy or Strong Buy versus six Holds. The average target of $386.28 implies meaningful upside from recent trading levels, although several firms have lowered their individual targets. Are Wall Street Analysts Predicting Stryker Stock Will Climb or Sink?
• Neutral Sentiment: Stryker maintained its fiscal 2026 earnings guidance of $14.95 to $15.10 per share and recently declared a quarterly dividend of $0.88, equivalent to a 1.1% annual yield. Institutional ownership remains high at approximately 77%, indicating continued support from large investors.
• Negative Sentiment: Director Ronda Stryker sold a combined 350,000 shares for approximately $117.8 million across August 18–19. Although she still owns more than 2.25 million shares, the transactions reduced her direct ownership and may raise caution among investors. Stryker Director Sells Shares
• Negative Sentiment: Recent commentary highlights execution risks, including cyber and supply-chain disruptions, while analysts have trimmed targets after an imperfect second quarter. BTIG reduced its target to $358 and JPMorgan lowered its target to $350, contributing to near-term pressure despite their Buy and Overweight ratings. Stryker Sell-Off Analysis

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on SYK. Robert W. Baird set a $385.00 price target on shares of Stryker in a research note on Friday, May 1st. Citizens Jmp decreased their target price on shares of Stryker from $440.00 to $400.00 and set a "market outperform" rating for the company in a report on Monday, August 3rd. Royal Bank Of Canada dropped their target price on shares of Stryker from $435.00 to $420.00 and set an "outperform" rating on the stock in a research note on Friday, July 31st. Raymond James Financial set a $370.00 price target on shares of Stryker in a report on Friday, July 31st. Finally, Wells Fargo & Company reduced their price target on shares of Stryker from $456.00 to $418.00 and set an "overweight" rating for the company in a research report on Friday, May 1st. One analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have given a Hold rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $386.28.

Insider Buying and Selling at Stryker

In other news, VP Robert S. Fletcher sold 4,544 shares of the firm's stock in a transaction on Thursday, May 28th. The stock was sold at an average price of $306.87, for a total value of $1,394,417.28. Following the transaction, the vice president directly owned 10,582 shares in the company, valued at $3,247,298.34. This trade represents a 30.04% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Debra King sold 826 shares of Stryker stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $336.30, for a total value of $277,783.80. Following the completion of the sale, the insider directly owned 6,210 shares of the company's stock, valued at $2,088,423. The trade was a 11.74% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 665,370 shares of company stock worth $216,238,501. Insiders own 4.60% of the company's stock.

Stryker Price Performance

Shares of NYSE:SYK opened at $329.86 on Monday. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.33 and a current ratio of 2.16. The firm has a market cap of $126.52 billion, a price-to-earnings ratio of 34.18, a price-to-earnings-growth ratio of 2.10 and a beta of 0.76. The business has a 50-day simple moving average of $326.99 and a two-hundred day simple moving average of $332.39. Stryker Corporation has a fifty-two week low of $281.00 and a fifty-two week high of $396.86.

Stryker (NYSE:SYK - Get Free Report) last announced its quarterly earnings results on Thursday, July 30th. The medical technology company reported $3.69 EPS for the quarter, topping analysts' consensus estimates of $3.49 by $0.20. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The firm had revenue of $6.59 billion during the quarter, compared to analyst estimates of $6.58 billion. During the same period in the previous year, the business posted $3.13 earnings per share. The business's revenue for the quarter was up 9.4% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. On average, analysts expect that Stryker Corporation will post 15.02 earnings per share for the current year.

Stryker Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be given a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a yield of 1.1%. The ex-dividend date of this dividend is Wednesday, September 30th. Stryker's payout ratio is 36.48%.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons' offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Corporation (NYSE:SYK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source